With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer

It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017.

The FDA has approved Onivyde as part of a multidrug combination, dubbed Nalirifox, to treat patients with newly diagnosed metastatic pancreatic cancer. Before Tuesday’s approval, Onivyde had been allowed for patients with previously treated disease since 2015.